Inclusion Criteria:

        Cisplatin Combination Expansion:

        Arm 1:Patients with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic
        setting; Arm 2: Patients with TNBC and one or two prior cytotoxic therapies in the
        metastatic setting.

          -  Arm A: castrate resistant prostate cancer, advanced breast cancer, or non-small cell
             lunch cancer that are candidates for treatment with a docetaxel-based combination.

          -  Arm B: Urothelial transitional cell cancer, triple negative breast cancer, ovarian
             cancer or non small cell lunch cancer that are candidates for a cisplatin-based
             combination.

          -  Arm C: Her2+ breast cancer refractory to prior herceptin or lapatinib, her2+
             esophagal-gastric cancer, head and neck squamous cell cancer, or non small cell lunch
             cancer that are candidates for treatment with a dacomitinib-based combination.

          -  Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not
             available.

          -  Eastern Cooperative Oncology Group [ECOG] performance must be 0 or 1.

          -  Adequate bone marrow, renal and liver function.

        Exclusion Criteria:

          -  Prior therapy for Cisplatin Combination Expansion:

               -  Prior platinum (carboplatin or cisplatin) in either the adjuvant or metastatic
                  setting;

               -  Prior radiation to >25% bone marrow as estimated by the Investigator.

          -  Patients with known symptomatic brain metastases.

          -  Chemotherapy, radiotherapy, biologics or investigational agent within 4 weeks of the
             lead-in dose.

          -  Major surgery within 4 weeks of the baseline disease assessments.

          -  >2 prior regimens containing cytotoxic chemotherapy in the metastatic setting.

          -  Active bacterial, fungal or viral infection.

          -  Uncontrolled or significant cardiovascular disease.